Peptic Ulcer Drugs Market Share

Global Peptic Ulcer Drugs Market Overview

Peptic Ulcer Drugs Market Size was valued at USD 5.07 Billion in 2023. The Global Peptic Ulcer Drugs industry is projected to grow from USD 5.37 Billion in 2024 to USD 7.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.18% during the forecast period (2024 - 2032).Infrastructure spending for healthcare is rising, and gastric ulcers are becoming more common; these are the key market drivers enhancing market growth.

on August 2023, Dr Reddy's Laboratories, a leading pharmaceutical company, announced the release of generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules on the US market. These capsules are used to treat stomach ulcers, irritable bowel syndrome, and inflammation of the colon. Dr Reddy's Laboratories said in a regulatory filing that they have introduced Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules USP, 5 mg/2.5 mg, in the US market.

In April 2023, Akums Drugs & Pharmaceutical revealed the introduction of their newest product, a distinctive Combikit consisting of Amoxicillin, Clarithromycin, and Esomeprazole. Akums has introduced the first-of-its-kind Combikit in India. Combikit (Amoxicillin + Clarithromycin + Esomeprazole) has been authorized by the CDSCO for the treatment of duodenal ulcers caused by Helicobacter pylori (H. pylori) and for the elimination of H. pylori. Helicobacter pylori in individuals with either current or previously treated peptic ulcer. The H. The efficacy of pylori eradication therapy in reducing the risk of ulcer recurrence has been demonstrated, offering significant benefits to patients. The user's text is a single letter, "H." Helicobacter pylori is a highly prevalent infection in India, known to contribute to the development of gastritis and peptic ulcers in people. The Combikit consists of three potent medications - Amoxicillin, Clarithromycin, and Esomeprazole. It functions by suppressing the proliferation of H. The pylori bacteria are suppressed, leading to a decrease in the secretion of gastric acid. The medication is provided in a pack that is handy for patients, containing all the necessary doses for a full treatment regimen.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Peptic Ulcer Drugs Market Trends

• Infrastructure spending for healthcare is rising to boost the market growth

A peptic ulcer is an open sore that forms on the inner lining of the stomach and harms the duodenum, esophagus, and stomach. The pathogenic Helicobacter pylori (H. pylori) or the overuse of painkillers may contribute to this disorder (Pylori). This medical condition can potentially worsen and cause stomach holes and significant harm to the upper duodenum, lower esophagus, and stomach. To treat such a problem and prevent such severe consequences, various medications are used. The market for medications for peptic ulcers is growing quickly and is anticipated to increase significantly over the coming years. The increased prevalence of peptic ulcers, the rising elderly population, and product innovations may contribute to this market expansion. Additional factors include growing R&D activity, a strong product pipeline, and rising triple treatment adoption. Increased corporate and government efforts, financing, and investments also boost the development of the peptic medication market.

Due to factors like rising peptic ulcer prevalence, expanding R&D due to government support and policies, and rising adoption of triple therapy, the market for peptic ulcer medications is expanding rapidly. For instance, a study in the International Journal of Microbiology found that about 10% of people worldwide suffer from peptic ulcers, one of the most common gastrointestinal disorders. Open sores called peptic ulcers to form on the inner lining of the stomach and upper small intestine. These ulcers are most frequently brought on by Helicobacter pylori infection and chronic aspirin and non-steroidal anti-inflammatory drug (NSAID) use. A wide range of over-the-counter drugs is available to treat peptic ulcer disease. Over-the-counter steroidal anti-inflammatory drugs approved for the general public are more widely used and well-liked because they make healthcare more affordable and accessible. Antacids (e.g., g. H2-receptor antagonists and antibiotics (e.g., PPIs (e.g., Zantac) and proton pump inhibitors (e.g., Losec) are over-the-counter medications. Many pharmaceutical companies are investing in over-the-counter versions of peptic ulcer medications to fuel market expansion in the ensuing years. For instance, Strides Shasun, a significant figure in the U.S. S. The OTC version of the drug Ranitidine for gastric ulcers was introduced into the market by Ranitidine has enhanced the Peptic Ulcer Drugs market CAGR across the globe in recent years.

Peptic Ulcer Drugs Market Segment Insights

Peptic Ulcer Drugs Pharmacological Class Insights

Based on the Pharmacological class, the Peptic Ulcer Drugs market segmentation includes Proton pump inhibitors (PPs), Anti-histamines, H2 antagonists, Antacids, and Others. The anterior Peptic Ulcer Drugs segment held the majority share in 2022 contribution concerning the Peptic Ulcer Drugs market revenue. Drugs called proton pump inhibitors (PPIs) lessen the amount of stomach acid produced by glands in your stomach lining.

Peptic Ulcer Drugs Clinical Insights

Based on Clinical, the Peptic Ulcer Drugs market segmentation includes gastric ulcers, duodenal ulcers, and esophageal ulcers. The Duodenal ulcer segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period 2024-2032 due to duodenal ulcers' high prevalence and the public's growing knowledge of new treatments for them, which is one of the causes of that prevalence. Heavy cigarette smoking, binge drinking, high-stress levels, a diet high in greasy and spicy foods, and many other risk factors contribute to developing duodenal ulcers. Because stomach ulcers occur more frequently, gastric ulcers account for the second-largest revenue share in the market for peptic ulcer medications implants for Peptic Ulcer Drugs, positively impacting the market growth.

Figure 1: Peptic Ulcer Drugs Market, by Clinical, 2023 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Peptic Ulcer Drugs Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Peptic Ulcer Drugs market accounted for USD 1.9 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Segment growth can be attributed to several variables, including the high prevalence of peptic ulcers, a sizable elderly population, and advanced healthcare infrastructure. Due to high healthcare spending, a surge in R&D activities, and technological advancement, the market in North America is growing. The industry is also expected to benefit from a wide range of market players and a rise in novel product approvals. Due to its highly developed healthcare infrastructure and high healthcare spending, Europe is the second-largest market participant.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: PEPTIC ULCER DRUGS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s Peptic Ulcer Drugs market accounts for the second-largest market share. The main industry players are investing in R&D because of the rising incidence of peptic ulcer disease worldwide. This causes new peptic ulcer disease drugs to be introduced, which benefits market expansion. Further, the Germany Peptic Ulcer Drugs market held the largest market share, and the UK Peptic Ulcer Drugs market was the fastest-growing market in the European region.

The Asia-Pacific Peptic Ulcer Drugs Market is expected to grow at the fastest CAGR from 2024 to 2032. Its population is aging rapidly, the healthcare sector is changing quickly, and new technologies are being used more frequently. Increased medical tourism and healthcare spending for better medical facilities drive the Asia Pacific peptic ulcer medication market. Moreover, the China Peptic Ulcer Drugs market held the largest market share, and the India Peptic Ulcer Drugs market was the fastest-growing market in the Asia-Pacific region.

Peptic Ulcer Drugs Key Market Players & Competitive Insights

Major market players are spending much on R&D to increase their product lines, which will help the Peptic Ulcer Drugs market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Peptic Ulcer Drugs industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Peptic Ulcer Drugs industry to benefit clients and expand the market sector. The Peptic Ulcer Drugs industry has provided medicine with significant benefits in recent years. The Peptic Ulcer Drugs market major player such as Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB, Eumedica Pharmaceuticals, and others are working on expanding the market demand by investing in research and development activities.

Sanofi S.A. We are a cutting-edge healthcare organization whose sole motivation is to pursue scientific breakthroughs to enhance people's quality of life. Our teams work to change the way medicine is done so that patients can have the unthinkable made possible. Millions of people benefit from our life-saving vaccines and potentially life-changing treatments, and some of the world's poorest nations have affordable access to our medications.

Also, Novartis AG To better and lengthen people's lives, we want to reimagine medicine. We tackle some of society's most difficult healthcare problems using cutting-edge science and technology. We find and create novel ways to deliver ground-breaking treatments to as many patients as possible. We also want to thank those who contribute time, money, and ideas to our business. Strategic priorities that support these focus areas determine how we will carry out our strategy. Thanks to our ongoing commitment to innovation, Novartis has one of the most aggressive pipelines in the sector. Many of these projects are for drugs that have the potential to improve treatment standards for patients all over the world significantly. These projects include new molecular entities, additional indications, and new formulations for marketed products. An overview of a few current projects is given in this table. The Novartis Pipeline data is updated every three months, so kindly take note.

Key Companies in the Peptic Ulcer Drugs market include

• Novartis AG


• Daiichi Sankyo Company Limited


• Acetelion Ltd, Boehringer Ingelheim


• Sanofi S.A.


• Astra Zeneca plc


• Ranbaxy Laboratories Limited, Inc.


• Takeda Pharmaceuticals Company Limited


• Pfizer Inc. Helicure AB


• Eumedica Pharmaceuticals

Peptic Ulcer Drugs Industry Developments

March 2021:At Northwell Health in New York City, famotidine, a medication commonly used to treat stomach ulcers, is being researched as a potential coronavirus treatment.

June 2021:Researchers at the Michael E. RHB-105, a three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule that successfully cures adults of Helicobacter pylori infection, has been approved by the FDA for use by De-Bakey Veterans Affairs Medical Center.

2021:Misoprostol tablets manufactured by Zydus Cadila were given US FDA approval to treat stomach ulcers.

Peptic Ulcer Drugs Market Segmentation

Peptic Ulcer Drugs Pharmacological class Outlook

• 
  

  Proton pump inhibitors (PPs)

  
  


• 
  

  Anti-histamines

  
  


• 
  

  H2 antagonists

  
  


• 
  

  Antacids

  
  


• 
  

  Others

  
  

Peptic Ulcer Drugs Clinical Outlook

• 
  

  Gastric ulcers

  
  


• 
  

  Duodenal ulcer

  
  


• 
  

  Esophageal ulcer

  
  

Peptic Ulcer Drugs Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America